APO RESEARCH · REPORT
PD-L1 and PIK3CA Testing
PD-L1 Biomarker Testing measures the amount of PDL1 on cancer cells. PDL1 is a protein that helps keep immune cells from attacking nonharmful cells in the body. Normally, the immune system fights foreign substances like viruses and bacteria, and not your own healthy cells. Some cancer cells have high amounts of PDL1. This allows the cancer cells to "trick" the immune system, and avoid being attacked as foreign, harmful substances.
Product & engineering
Understand the product.
PD-L1 Biomarker Testing measures the amount of PDL1 on cancer cells. PDL1 is a protein that helps keep immune cells from attacking nonharmful cells in the body. Normally, the immune system fights foreign substances like viruses and bacteria, and not your own healthy cells. Some cancer cells have high amounts of PDL1. This allows the cancer cells to "trick" the immune system, and avoid being attacked as foreign, harmful substances.
Current PD-L1 testing is based on immunohistochemistry (IHC) methods. Immunohistochemistry (IHC) is the process whereby antibodies are used to detect proteins (antigens) in cells within a tissue section (for instance liver, pancreas or the heart).
PD-L1 is a ligand that binds to PD-1 (programmed cell death-1), expressed on activated T cells, to evade anti-tumor responses. PD-L1 plays a role in inhibiting T cell activation and proliferation and has emerged as an important target in cancer treatment. PD-L1 protein detection by immunohistochemistry (IHC) testing is widely used as a predictive biomarker assay for anti–PD-1/PD-L1 therapies.
PIK3CA is a gene that encodes a lipid kinase involved in multiple signaling pathways. These pathways influence cellular functions such as growth, death, and proliferation. PIK3CA mutations activate the PI3K-PTEN-AKT pathway, which is downstream from both the EGFR and the RAS-RAF-MAPK pathways. PIK3CA mutations may cause oncogenic transformation independent of RAS or RAF mutations.
PIK3CA mutations occur in about 15% to 30% of breast, endometrial, and colon cancers. They occur less frequently in lung cancer and other types of cancer. Presence of PIK3CA mutations is associated with poor prognosis and lack of response to specific therapies in patients with breast, endometrial, or colon cancer.
Selected research
Market Structure
Global PD-L1 and PIK3CA Testing Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
PD-L1 Biomarker Testing measures the amount of PDL1 on cancer cells. PDL1 is a protein that helps keep immune cells from attacking nonharmful cells in the body. Normally, the immune system fights foreign substances like viruses and bacteria, and not your own healthy cells. Some cancer cells have high amounts of PDL1. This allows the cancer cells to "trick" the immune system, and avoid being attacked as foreign, harmful substances.
Current PD-L1 testing is based on immunohistochemistry (IHC) methods. Immunohistochemistry (IHC) is the process whereby antibodies are used to detect proteins (antigens) in cells within a tissue section (for instance liver, pancreas or the heart).
PD-L1 is a ligand that binds to PD-1 (programmed cell death-1), expressed on activated T cells, to evade anti-tumor responses. PD-L1 plays a role in inhibiting T cell activation and proliferation and has emerged as an important target in cancer treatment. PD-L1 protein detection by immunohistochemistry (IHC) testing is widely used as a predictive biomarker assay for anti–PD-1/PD-L1 therapies.
Read the full market overview
PIK3CA is a gene that encodes a lipid kinase involved in multiple signaling pathways. These pathways influence cellular functions such as growth, death, and proliferation. PIK3CA mutations activate the PI3K-PTEN-AKT pathway, which is downstream from both the EGFR and the RAS-RAF-MAPK pathways. PIK3CA mutations may cause oncogenic transformation independent of RAS or RAF mutations.
PIK3CA mutations occur in about 15% to 30% of breast, endometrial, and colon cancers. They occur less frequently in lung cancer and other types of cancer. Presence of PIK3CA mutations is associated with poor prognosis and lack of response to specific therapies in patients with breast, endometrial, or colon cancer.
The classification of PD-L1 and PIK3CA Testing Product includes PD-L1 Testing and PIK3CA Testing. PD-L1 accounted for a share of 80% in the global PD-L1 and PIK3CA Testing Product market.
PD-L1 and PIK3CA Testing Product is widely used in Hospital, Diagnostic Center and Other. In PD-L1 and PIK3CA Testing Product market, the Diagnostic Center holds an important share in terms of Application.
North America is the largest consumption place, with a market share nearly 57% . Following North America, Europe is the second largest consumption place with the market share of 28%.
Market competition is intense. Agilent Technologies, Roche, QIAGEN, Amoy Diagnostics, ACCB Biotech, etc. The top five vendors held 84% of the market share.
Report Includes
This report provides an overview of the global PD-L1 and PIK3CA Testing market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of PD-L1 and PIK3CA Testing and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents PD-L1 and PIK3CA Testing revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the PD-L1 and PIK3CA Testing market size, projected growth trends, production technologies, key applications, and end-use industries.
PD-L1 and PIK3CA Testing Segment by Company
Agilent Technologies
Roche
QIAGEN
EntroGen
Amoy Diagnostics
ACCB Biotech
PD-L1 and PIK3CA Testing Segment by Type
PD-L1 Testing
PIK3CA Testing
PD-L1 and PIK3CA Testing Segment by Application
Hospital
Diagnostic Center
Others
PD-L1 and PIK3CA Testing Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PD-L1 and PIK3CA Testing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of PD-L1 and PIK3CA Testing and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PD-L1 and PIK3CA Testing.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of PD-L1 and PIK3CA Testing in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global PD-L1 and PIK3CA Testing industry.
Chapter 3: Detailed analysis of PD-L1 and PIK3CA Testing companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, PD-L1 and PIK3CA Testingrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- PD-L1 Testing
- PIK3CA Testing
Applications
- Hospital
- Diagnostic Center
- Others
Companies covered
- Agilent Technologies
- Roche
- QIAGEN
- EntroGen
- Amoy Diagnostics
- ACCB Biotech
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global PD-L1 and PIK3CA Testing Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 PD-L1 Testing
- 1.2.3 PIK3CA Testing
- 1.3 Market Analysis by Application
- 1.3.1 Global PD-L1 and PIK3CA Testing Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Hospital
- 1.3.3 Diagnostic Center
- 1.3.4 Others
- 1.4 Global Market Growth Prospects
- 1.5 Global PD-L1 and PIK3CA Testing Growth Trends by Region
- 1.5.1 Global PD-L1 and PIK3CA Testing Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 PD-L1 and PIK3CA Testing Market Size by Region (2021-2026)
- 1.5.3 PD-L1 and PIK3CA Testing Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global PD-L1 and PIK3CA Testing Market Dynamics
- 2.1 PD-L1 and PIK3CA Testing Industry Trends
- 2.2 PD-L1 and PIK3CA Testing Industry Drivers
- 2.3 PD-L1 and PIK3CA Testing Industry Opportunities and Challenges
- 2.4 PD-L1 and PIK3CA Testing Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global PD-L1 and PIK3CA Testing Revenue by Company (2021-2026)
- 3.2 Global PD-L1 and PIK3CA Testing Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global PD-L1 and PIK3CA Testing Key Company Head office and Area Served
- 3.4 Global PD-L1 and PIK3CA Testing Company, Product Type & Application
- 3.5 Global PD-L1 and PIK3CA Testing Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global PD-L1 and PIK3CA Testing Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 PD-L1 and PIK3CA Testing Players Market Share by Revenue in 2025
- 3.6.3 2025 PD-L1 and PIK3CA Testing Tier 1, Tier 2, and Tier 3
4 PD-L1 and PIK3CA Testing Market by Type
- 4.1 Global PD-L1 and PIK3CA Testing Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global PD-L1 and PIK3CA Testing Market Size by Type (2021-2032)
- 4.3 Global PD-L1 and PIK3CA Testing Market Size Share by Type (2021-2032)
5 PD-L1 and PIK3CA Testing Market by Application
- 5.1 Global PD-L1 and PIK3CA Testing Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global PD-L1 and PIK3CA Testing Market Size by Application (2021-2032)
- 5.3 Global PD-L1 and PIK3CA Testing Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Agilent Technologies
- 6.1.1 Agilent Technologies Company Information
- 6.1.2 Agilent Technologies Business Overview
- 6.1.3 Agilent Technologies PD-L1 and PIK3CA Testing Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Agilent Technologies PD-L1 and PIK3CA Testing Product Portfolio
- 6.1.5 Agilent Technologies Recent Developments
- 6.2 Roche
- 6.2.1 Roche Company Information
- 6.2.2 Roche Business Overview
- 6.2.3 Roche PD-L1 and PIK3CA Testing Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Roche PD-L1 and PIK3CA Testing Product Portfolio
- 6.2.5 Roche Recent Developments
- 6.3 QIAGEN
- 6.3.1 QIAGEN Company Information
- 6.3.2 QIAGEN Business Overview
- 6.3.3 QIAGEN PD-L1 and PIK3CA Testing Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 QIAGEN PD-L1 and PIK3CA Testing Product Portfolio
- 6.3.5 QIAGEN Recent Developments
- 6.4 EntroGen
- 6.4.1 EntroGen Company Information
- 6.4.2 EntroGen Business Overview
- 6.4.3 EntroGen PD-L1 and PIK3CA Testing Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 EntroGen PD-L1 and PIK3CA Testing Product Portfolio
- 6.4.5 EntroGen Recent Developments
- 6.5 Amoy Diagnostics
- 6.5.1 Amoy Diagnostics Company Information
- 6.5.2 Amoy Diagnostics Business Overview
- 6.5.3 Amoy Diagnostics PD-L1 and PIK3CA Testing Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 Amoy Diagnostics PD-L1 and PIK3CA Testing Product Portfolio
- 6.5.5 Amoy Diagnostics Recent Developments
- 6.6 ACCB Biotech
- 6.6.1 ACCB Biotech Company Information
- 6.6.2 ACCB Biotech Business Overview
- 6.6.3 ACCB Biotech PD-L1 and PIK3CA Testing Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 ACCB Biotech PD-L1 and PIK3CA Testing Product Portfolio
- 6.6.5 ACCB Biotech Recent Developments
7 North America
- 7.1 North America PD-L1 and PIK3CA Testing Market Size (2021-2032)
- 7.2 North America PD-L1 and PIK3CA Testing Market Size by Type
- 7.2.1 North America PD-L1 and PIK3CA Testing Market Size by Type (2021-2026)
- 7.2.2 North America PD-L1 and PIK3CA Testing Market Size by Type (2027-2032)
- 7.2.3 North America PD-L1 and PIK3CA Testing Market Share by Type (2021-2032)
- 7.3 North America PD-L1 and PIK3CA Testing Market Size by Application
- 7.3.1 North America PD-L1 and PIK3CA Testing Market Size by Application (2021-2026)
- 7.3.2 North America PD-L1 and PIK3CA Testing Market Size by Application (2027-2032)
- 7.3.3 North America PD-L1 and PIK3CA Testing Market Share by Application (2021-2032)
- 7.4 North America PD-L1 and PIK3CA Testing Market Size by Country
- 7.4.1 North America PD-L1 and PIK3CA Testing Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America PD-L1 and PIK3CA Testing Market Size by Country (2021-2026)
- 7.4.3 North America PD-L1 and PIK3CA Testing Market Size by Country (2027-2032)
- 7.4.4 North America PD-L1 and PIK3CA Testing Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe PD-L1 and PIK3CA Testing Market Size (2021-2032)
- 8.2 Europe PD-L1 and PIK3CA Testing Market Size by Type
- 8.2.1 Europe PD-L1 and PIK3CA Testing Market Size by Type (2021-2026)
- 8.2.2 Europe PD-L1 and PIK3CA Testing Market Size by Type (2027-2032)
- 8.2.3 Europe PD-L1 and PIK3CA Testing Market Share by Type (2021-2032)
- 8.3 Europe PD-L1 and PIK3CA Testing Market Size by Application
- 8.3.1 Europe PD-L1 and PIK3CA Testing Market Size by Application (2021-2026)
- 8.3.2 Europe PD-L1 and PIK3CA Testing Market Size by Application (2027-2032)
- 8.3.3 Europe PD-L1 and PIK3CA Testing Market Share by Application (2021-2032)
- 8.4 Europe PD-L1 and PIK3CA Testing Market Size by Country
- 8.4.1 Europe PD-L1 and PIK3CA Testing Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe PD-L1 and PIK3CA Testing Market Size by Country (2021-2026)
- 8.4.3 Europe PD-L1 and PIK3CA Testing Market Size by Country (2027-2032)
- 8.4.4 Europe PD-L1 and PIK3CA Testing Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China PD-L1 and PIK3CA Testing Market Size (2021-2032)
- 9.2 China PD-L1 and PIK3CA Testing Market Size by Type
- 9.2.1 China PD-L1 and PIK3CA Testing Market Size by Type (2021-2026)
- 9.2.2 China PD-L1 and PIK3CA Testing Market Size by Type (2027-2032)
- 9.2.3 China PD-L1 and PIK3CA Testing Market Share by Type (2021-2032)
- 9.3 China PD-L1 and PIK3CA Testing Market Size by Application
- 9.3.1 China PD-L1 and PIK3CA Testing Market Size by Application (2021-2026)
- 9.3.2 China PD-L1 and PIK3CA Testing Market Size by Application (2027-2032)
- 9.3.3 China PD-L1 and PIK3CA Testing Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia PD-L1 and PIK3CA Testing Market Size (2021-2032)
- 10.2 Asia PD-L1 and PIK3CA Testing Market Size by Type
- 10.2.1 Asia PD-L1 and PIK3CA Testing Market Size by Type (2021-2026)
- 10.2.2 Asia PD-L1 and PIK3CA Testing Market Size by Type (2027-2032)
- 10.2.3 Asia PD-L1 and PIK3CA Testing Market Share by Type (2021-2032)
- 10.3 Asia PD-L1 and PIK3CA Testing Market Size by Application
- 10.3.1 Asia PD-L1 and PIK3CA Testing Market Size by Application (2021-2026)
- 10.3.2 Asia PD-L1 and PIK3CA Testing Market Size by Application (2027-2032)
- 10.3.3 Asia PD-L1 and PIK3CA Testing Market Share by Application (2021-2032)
- 10.4 Asia PD-L1 and PIK3CA Testing Market Size by Country
- 10.4.1 Asia PD-L1 and PIK3CA Testing Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia PD-L1 and PIK3CA Testing Market Size by Country (2021-2026)
- 10.4.3 Asia PD-L1 and PIK3CA Testing Market Size by Country (2027-2032)
- 10.4.4 Asia PD-L1 and PIK3CA Testing Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa PD-L1 and PIK3CA Testing Market Size (2021-2032)
- 11.2 South America, Middle East & Africa PD-L1 and PIK3CA Testing Market Size by Type
- 11.2.1 South America, Middle East & Africa PD-L1 and PIK3CA Testing Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa PD-L1 and PIK3CA Testing Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa PD-L1 and PIK3CA Testing Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa PD-L1 and PIK3CA Testing Market Size by Application
- 11.3.1 South America, Middle East & Africa PD-L1 and PIK3CA Testing Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa PD-L1 and PIK3CA Testing Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa PD-L1 and PIK3CA Testing Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa PD-L1 and PIK3CA Testing Market Size by Country
- 11.4.1 South America, Middle East & Africa PD-L1 and PIK3CA Testing Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa PD-L1 and PIK3CA Testing Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa PD-L1 and PIK3CA Testing Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa PD-L1 and PIK3CA Testing Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst